Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin + BR or BG in R/R FL or DLBCL
NCT02257567Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2014
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 13
01
Overview
A Phase 2 trial of polatuzumab vedotin in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Oct 2014; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02257567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257567.